Dr. Scholz on Significance of ARAMIS Trial in CRPC

Mark Scholz, MD
Published: Wednesday, Mar 13, 2019



Mark Scholz, MD, medical director, Prostate Oncology Specialists, discusses the significance of the ARAMIS trial in the treatment of patients with nonmetastatic castration-resistant prostate cancer (CRPC).

This is an exciting time in terms of leveraging effective treatment options, Scholz says. In the ARAMIS study, results of which were presented at the 2019 Genitourinary Cancers Symposium, researchers were looking at a third androgen receptor (AR) inhibitor, darolutamide. The hope was that darolutamide would match the efficacy of apalutamide (Erleada) and enzalutamide (Xtandi) and be free of the toxicities these 2 drugs are associated with.

Scholz says that these studies consistently emphasize the importance of getting these patients on therapy earlier, such as at the first sign of rising prostate-specific antigen levels and hormone resistance. While the AR inhibitors have shown practice-changing benefit, he notes that only about 25% of patients start therapy with these agents in a timely fashion. In general, these drugs are tolerable and effective in delaying time to metastases by about 2 years. Trials like ARAMIS show that patients with nonmetastatic CRPC need to be treated more aggressively, Scholz concludes.
SELECTED
LANGUAGE


Mark Scholz, MD, medical director, Prostate Oncology Specialists, discusses the significance of the ARAMIS trial in the treatment of patients with nonmetastatic castration-resistant prostate cancer (CRPC).

This is an exciting time in terms of leveraging effective treatment options, Scholz says. In the ARAMIS study, results of which were presented at the 2019 Genitourinary Cancers Symposium, researchers were looking at a third androgen receptor (AR) inhibitor, darolutamide. The hope was that darolutamide would match the efficacy of apalutamide (Erleada) and enzalutamide (Xtandi) and be free of the toxicities these 2 drugs are associated with.

Scholz says that these studies consistently emphasize the importance of getting these patients on therapy earlier, such as at the first sign of rising prostate-specific antigen levels and hormone resistance. While the AR inhibitors have shown practice-changing benefit, he notes that only about 25% of patients start therapy with these agents in a timely fashion. In general, these drugs are tolerable and effective in delaying time to metastases by about 2 years. Trials like ARAMIS show that patients with nonmetastatic CRPC need to be treated more aggressively, Scholz concludes.

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Oncology Briefings™: Current Perspectives on Preventing and Managing Tumor Lysis SyndromeJun 30, 20191.0
Community Practice Connections™: 2nd Annual International Congress on Oncology Pathology™Aug 31, 20191.5
Publication Bottom Border
Border Publication
x